References
1. Caudill-Slosberg, M.A., L.M. Schwartz, and S.J.P. Woloshin,Office visits and analgesic prescriptions for musculoskeletal pain
in US: 1980 vs. 2000. 2004. 109 (3): p. 514-519.
2. Dewire, S.M., et al., A G protein-biased ligand at the μ-opioid
receptor is potently analgesic with reduced gastrointestinal and
respiratory dysfunction compared with morphine. 2013. 344 (3):
p. 708-717.
3. Violin, J.D. and R.J. Lefkowitz, β-Arrestin-biased ligands at
seven-transmembrane receptors. 2007.
4. Matthes, H.W.D., et al., Loss of morphine-induced analgesia,
reward effect and withdrawal symptoms in mice lacking the
|[micro]|-opioid-receptor gene. 1996.383 (6603): p. 819.
5. Pasternak, G.W. and Y.X.J.P.R. Pan, Mu Opioids and Their
Receptors: Evolution of a Concept. 2013. 65 (4): p. 1257.
6. Shabalina, S.A., et al., Expansion of the human μ-opioid
receptor gene architecture: novel functional variants. 2009.18 (6): p. 1037-1051.
7. Xu, J., et al., Isolating and characterizing three
alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and
mMOR-1P. 2014.
8. Xu, J., et al., Identification and characterization of seven
new exon 11-associated splice variants of the rat mu opioid receptor
gene, OPRM1. 2011.
9. Majumdar, S., et al., Truncated G protein-coupled mu opioid
receptor MOR-1 splice variants are targets for highly potent opioid
analgesics lacking side effects.
10. Lu, Z., et al., Mediation of opioid analgesia by a truncated
6-transmembrane GPCR. 2015. 125 (7): p. 2626-30.
11. Pan, Y., et al., Involvement of exon 11-associated variants of
the mu opioid receptor MOR-1 in heroin, but not morphine, actions.2009. 106 (12): p. 4917-4922.
12. Olawore, N.O., et al., Chemical composition of the leaf and
fruit essential oils of Murraya paniculata (L.) Jack. (Syn. Murraya
exotica Linn.). 2005. 20 (1): p. 54-56.
13. Bishay, D., et al., PHYTOCHEMICAL STUDY OF MURRAYA EXOTICA L.
CULTIVATED IN EGYPT II- COUMARINS OF THE LEAVES. 1988. 11 (1):
p. 88-104.
14. Wu, L., et al., Evaluation of anti-inflammatory and
antinociceptive activities of Murraya exotica. 2010. 48 (12):
p. 1344-53.
15. F., et al., Composition and antimicrobial activity of the
essential oil of Murraya exotica L. 1998.
16. Kong, Y.C., et al., A chemotaxonomic division of Murraya based
on the distribution of the alkaloids yuehchukene and girinimbine. 1986.14 (5): p. 491-497.
17. Ganguly, S.N. and A.J.P. Sarkar, Exozoline, a new carbazole
alkaloid from the leaves of Murraya exotica. 1978. 17 (10): p.
1816-1817.
18. Teshima, N., et al., Two New Biocoumarins from the Leaves of
Murraya exotica. 2005.
19. Shafiullah, S.M., et al., Polymethoxyflavones from Nicotiana
plumbaginifolia (Solanaceae) Exert Antinociceptive and
Neuropharmacological Effects in Mice. 2018. 9 : p. 85-.
20. Damour, F.E., D.L.J.J.o.P. Smith, and E. Therapeutics, A
METHOD FOR DETERMINING LOSS OF PAIN SENSATION. 1941. 72 (1): p.
74-79.
21. Ballesta, J., et al., Sensitivity to μ-opioid
receptor-mediated anti-nociception is determined by cross-regulation
between μ- and δ-opioid receptors at supraspinal level. 2012.166 (1): p. 309-326.
22. Gistrak, M.A., et al., Pharmacological actions of a novel
mixed opiate agonist/antagonist: naloxone benzoylhydrazone. 1989.251 (2): p. 469-476.
23. Ling, G.S.F., et al., Separation of morphine analgesia from
physical dependence. 1984. 226 (4673): p. 462-464.
24. Urs, et al., A Dopamine D1 Receptor-Dependent β-Arrestin
Signaling Complex Potentially Regulates Morphine-Induced Psychomotor
Activation but not Reward in Mice. 2011.
25. Majumdar, S., et al., Generation of novel radiolabeled opiates
through site-selective iodination. 2011. 21 (13): p. 4001-4004.
26. Grinnell, S.G., et al., Synthesis and Characterization of
Azido Aryl Analogs of IBNtxA for Radio-Photoaffinity Labeling Opioid
Receptors in Cell Lines and in Mouse Brain. 2020.
27. Chen, Y., et al., TRPV4 is necessary for trigeminal irritant
pain and functions as a cellular formalin receptor. 2014.155 (12): p. 2662-2672.
28. Islam, A., et al., Abuse Liability, Anti-Nociceptive, and
Discriminative Stimulus Properties of IBNtxA. 2020. XXXX (XXX).
29. Majumdar, S., et al., Truncated G protein-coupled mu opioid
receptor MOR-1 splice variants are targets for highly potent opioid
analgesics lacking side effects. 2011. 108 (49).
30. Wise, H.J.J.o.M.S., The roles played by highly truncated
splice variants of G protein-coupled receptors. 2012. 7 (1): p.
13-13.
31. Sora, I., et al., Opiate receptor knockout mice define μ
receptor roles in endogenous nociceptive responses and
morphine-inducedanalgesia. 1997. 94 (4): p. 1544-1549.
32. Majumdar, S., et al., Synthesis and Evaluation of
Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated
μ Opioid Receptor (MOR-1) Splice Variants. 2012. 55 (14): p.
6352-6362.
33. Wieskopf, J.S., et al., Broad-spectrum analgesic efficacy of
IBNtxA is mediated by exon 11-associated splice variants of the
mu-opioid receptor gene. 2014. 155 (10): p. 2063-2070.
34. Schuller, A.G.P., et al., Retention of heroin and morphine-6
beta-glucuronide analgesia in a new line of mice lacking exon 1 of
MOR-1. 1999. 2 (2): p. 151.